CN104582707B - 三嗪化合物 - Google Patents

三嗪化合物 Download PDF

Info

Publication number
CN104582707B
CN104582707B CN201380044355.4A CN201380044355A CN104582707B CN 104582707 B CN104582707 B CN 104582707B CN 201380044355 A CN201380044355 A CN 201380044355A CN 104582707 B CN104582707 B CN 104582707B
Authority
CN
China
Prior art keywords
compound
triazin
dimethylbenzamide
mmol
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380044355.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104582707A (zh
Inventor
松迪普·杜加尔
迪内希·马哈詹
弗兰克·霍林格彼得
阿米特·夏尔马
维纳亚克·特里帕蒂
比拉什·奎拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pivot Holdings LLC
Original Assignee
Sphaera Pharma Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphaera Pharma Pvt Ltd filed Critical Sphaera Pharma Pvt Ltd
Publication of CN104582707A publication Critical patent/CN104582707A/zh
Application granted granted Critical
Publication of CN104582707B publication Critical patent/CN104582707B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201380044355.4A 2012-07-23 2013-07-23 三嗪化合物 Active CN104582707B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2283DE2012 2012-07-23
IN2283/DEL/2012 2012-07-23
PCT/IN2013/000458 WO2014016849A2 (en) 2012-07-23 2013-07-23 Novel triazine compounds

Publications (2)

Publication Number Publication Date
CN104582707A CN104582707A (zh) 2015-04-29
CN104582707B true CN104582707B (zh) 2017-09-26

Family

ID=54187091

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380044355.4A Active CN104582707B (zh) 2012-07-23 2013-07-23 三嗪化合物

Country Status (6)

Country Link
US (1) US9630958B2 (enExample)
EP (1) EP2874632B1 (enExample)
JP (1) JP6175139B2 (enExample)
CN (1) CN104582707B (enExample)
IN (1) IN2015DN01408A (enExample)
WO (1) WO2014016849A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017009751A1 (en) * 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
ES2775775T3 (es) * 2016-09-13 2020-07-28 Covestro Deutschland Ag Uso de un polímero elástico para la producción de un cuerpo poroso en un procedimiento de fabricación aditiva
JP2019536767A (ja) * 2016-11-01 2019-12-19 スフェラ ファーマ ピーブイティー リミテッドＳｐｈａｅｒａ Ｐｈａｒｍａ Ｐｖｔ． Ｌｔｄ． エピカテキン及び抗癌化合物の組合せを含む組成物
CN106749081B (zh) * 2016-11-21 2019-06-25 浙江嘉圣生物医药有限公司 一种(s)-(4-溴-2-甲苯)(3-甲基吗啉)甲酮的制备方法
CN107266422A (zh) * 2017-06-12 2017-10-20 西安交通大学 2‑（5‑嘧啶基）‑4‑吗啉基‑6‑取代均三嗪类化合物及其盐、制备方法和应用
EP3676264A1 (en) * 2017-08-28 2020-07-08 Acurastem Inc. Pikfyve kinase inhibitors
CN109810100B (zh) * 2017-11-21 2022-03-11 中国药科大学 含有苯并呋喃的parp-1和pi3k双靶点抑制剂
CN108586446A (zh) * 2018-04-20 2018-09-28 湖南华腾制药有限公司 三嗪类化合物及其制备方法和抗肿瘤应用
UY39569A (es) 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas
CN113200969B (zh) * 2021-05-19 2022-11-25 中国药科大学 一种PI3Kα选择性抑制剂及其制备方法和应用
CN116239580B (zh) * 2023-03-06 2025-05-23 中国药科大学 三嗪类化合物及其制备方法、药物组合物和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
CN102209714A (zh) * 2008-11-10 2011-10-05 巴塞尔大学 三嗪、嘧啶和吡啶类似物和它们作为治疗剂和诊断探针的应用
WO2012101654A2 (en) * 2011-01-25 2012-08-02 Sphaera Pharma Pvt. Ltd Novel triazine compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0314196A (pt) * 2002-09-10 2005-07-26 Scios Inc Inibidores de tgf-beta
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2009248997A1 (en) * 2008-05-23 2009-11-26 Wyeth Llc Triazine compounds as PI3 kinase and mTOR inhibitors
CA2987503C (en) * 2009-07-07 2019-02-26 Mei Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
CN102209714A (zh) * 2008-11-10 2011-10-05 巴塞尔大学 三嗪、嘧啶和吡啶类似物和它们作为治疗剂和诊断探针的应用
WO2012101654A2 (en) * 2011-01-25 2012-08-02 Sphaera Pharma Pvt. Ltd Novel triazine compounds

Also Published As

Publication number Publication date
US20150197515A1 (en) 2015-07-16
WO2014016849A3 (en) 2014-06-19
EP2874632B1 (en) 2020-06-17
WO2014016849A9 (en) 2014-03-13
EP2874632A4 (en) 2016-03-16
JP2015526424A (ja) 2015-09-10
JP6175139B2 (ja) 2017-08-02
CN104582707A (zh) 2015-04-29
US9630958B2 (en) 2017-04-25
EP2874632A2 (en) 2015-05-27
WO2014016849A2 (en) 2014-01-30
IN2015DN01408A (enExample) 2015-07-03

Similar Documents

Publication Publication Date Title
CN104582707B (zh) 三嗪化合物
CN113382991B (zh) 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN109890819B (zh) 作为免疫调节剂的杂环化合物
JP2024020220A (ja) 免疫調節剤としての複素環式化合物
CN110891953B (zh) 吡咯并三嗪类衍生物、其制备方法及其用途
CN105503827B (zh) Egfr抑制剂及其制备方法和用途
CN110092787B (zh) 一种化合物或其药用盐或组合物的制备及应用
TW201833102A (zh) 作為ehmt2抑制劑之胺取代的雜環化合物及其使用方法
CN105188704A (zh) 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法
CN101790525A (zh) 药物化合物
TW200813042A (en) Six membered heteroaromatic inhibitors targeting resistant kinase mutations
CN115175902B (zh) 一类用作激酶抑制剂的化合物及其应用
IL277518B2 (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
CA3149846A1 (en) Quinoline derivatives as protein kinase inhibitors
US20160159774A1 (en) Heteroaryl compounds and uses thereof
CN104557871B (zh) 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途
CA2723279A1 (en) 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
CN111153891B (zh) 一种取代苯并咪唑类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
CA2687474A1 (en) Triazolyl aminopyrimidine compounds
CN118976029A (zh) 用于预防或治疗帕金森病或非酒精性脂肪性肝炎的药学组合物
CN115260211B (zh) 含噻吩稠环类衍生物、药物组合物及其制备方法和应用
CN114989173B (zh) 咪唑类化合物、其药物组合物及其用途
TWI894448B (zh) Ctla-4小分子降解劑及其應用
CN117105919A (zh) 一种靶向抗肿瘤药物及其在制备药物中的用途
AU2020324561B2 (en) Quinoline derivatives as protein kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240222

Address after: Singapore City

Patentee after: Pivot Investment Holdings Private Ltd.

Country or region after: Singapore

Address before: Singapore City

Patentee before: SPHAERA PHARMA Pvt.,Ltd.

Country or region before: Singapore

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240229

Address after: Nevada

Patentee after: Pivot Holdings LLC

Country or region after: U.S.A.

Address before: Singapore City

Patentee before: Pivot Investment Holdings Private Ltd.

Country or region before: Singapore